<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153777</url>
  </required_header>
  <id_info>
    <org_study_id>C03-090</org_study_id>
    <nct_id>NCT00153777</nct_id>
  </id_info>
  <brief_title>Cellulose Sulfate and HIV Transmission Among Women</brief_title>
  <official_title>Randomized Controlled Trial of 6% Cellulose Sulfate Gel and the Effect on Vaginal HIV Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CONRAD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CONRAD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of cellulose sulfate on the transmission
      of HIV to women via vaginal intercourse. The secondary objectives are the effect on the
      transmission of gonorrhea and chlamydia via the same route.

      The study hypothesis is that there will be no effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the availability of an effective HIV prevention method, i.e. the condom, the epidemic
      continues growing. There is thus an urgent need for additional HIV prevention methods. One of
      the possibilities is the use of microbicides, i.e. chemical products which may be used in the
      vagina or rectum with the potential to prevent HIV infection.

      Cellulose sulfate is an HIV entry inhibitor with an in vitro effect on N. gonorrhoeae (NG)
      and C. trachomatis (CT) and other sexually transmitted organisms.

      The study assess its effect on the vaginal transmission of HIV, NG and CT among women at high
      risk of heterosexual STI infection (defined as having had more than two partners in the last
      three months and an average of three sexual acts per week).

      The study is randomized, triple-blinded, placebo controlled.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    IDMC recommendation
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of HIV-1 and HIV-2 in the study.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-first incidental gonococcal or chlamydial infection.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1428</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cellulose Sulfate gel (6%)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 years old

          -  an average of at least three vaginal sex acts per week, at least three different
             partners in the last three months, expecting to continue this behavior

          -  HIV negative

          -  willing and able to comply with the protocol

        Exclusion Criteria:

          -  pregnancy

          -  allergy to latex or spermicides

          -  intravenous drug user
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lut Van Damme, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CONRAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Projet SIDA3</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karnataka Health Promotion Trust</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YRG Care</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Council</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makarere University - Mulago Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>India</country>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <removed_countries>
    <country>Burkina Faso</country>
  </removed_countries>
  <link>
    <url>http://www.conrad.org</url>
  </link>
  <reference>
    <citation>Crucitti T, Jespers V, Van Damme L, Van Dyck E, Buvé A. Vaginal microbicides can interfere with nucleic acid amplification tests used for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae infection. Diagn Microbiol Infect Dis. 2007 Jan;57(1):97-9. Epub 2006 Jul 21.</citation>
    <PMID>16860515</PMID>
  </reference>
  <reference>
    <citation>Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, Weiner DH, Hillier SL, Fichorova RN, Callahan M. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception. 2006 Aug;74(2):133-40. Epub 2006 May 2.</citation>
    <PMID>16860051</PMID>
  </reference>
  <reference>
    <citation>El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Mâsse B, Soto-Torres L, Kwiecien A. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006 May 12;20(8):1109-16.</citation>
    <PMID>16691061</PMID>
  </reference>
  <reference>
    <citation>Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, Chitlange S, Ali MM, Callahan M, Van Damme L. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS. 2005 Dec 2;19(18):2157-63.</citation>
    <PMID>16284466</PMID>
  </reference>
  <reference>
    <citation>Mauck C, Weiner DH, Ballagh S, Creinin M, Archer DF, Schwartz J, Pymar H, Lai JJ, Callahan M. Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception. 2001 Dec;64(6):383-91.</citation>
    <PMID>11834238</PMID>
  </reference>
  <reference>
    <citation>Mauck C, Frezieres R, Walsh T, Robergeau K, Callahan M. Cellulose sulfate: tolerance and acceptability of penile application. Contraception. 2001 Dec;64(6):377-81.</citation>
    <PMID>11834237</PMID>
  </reference>
  <reference>
    <citation>Anderson RA, Feathergill KA, Diao XH, Cooper MD, Kirkpatrick R, Herold BC, Doncel GF, Chany CJ, Waller DP, Rencher WF, Zaneveld LJ. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl. 2002 May-Jun;23(3):426-38.</citation>
    <PMID>12002445</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2015</last_update_posted>
  <keyword>HIV prevention</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Women</keyword>
  <keyword>Sexually transmitted infections</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

